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Abstract 
Background: Macular pigment (MP) has been related to the occurrence of age related macular degeneration 
(AMD). We investigated prospectively in eyes of elderly individuals how magnitude and spatial distribution of MP had 
changed after 4 years.
Methods: The study included 380 eyes from 237 participants of the Münster Ageing and Retina Study cohort which 
were free of advanced stages of AMD. MP optical density (MPOD) was measured in density units (D.U.) at eccentrici‑
ties of 0.25°, 0.5°, 1.0° and 2.0° from the fovea using dual‑wavelength autofluorescence; ring‑like MP distributions were 
identified from MP density profiles. Changes were assessed with mixed linear models.
Results: The study participants’ mean age at baseline was 70.5 years. Early AMD was present in 150 study eyes 
(39.5 %) and a ring‑like distribution of MPOD was found in 87 study eyes (22.9 %). After a median follow‑up time of 
3.96 years, the MPOD averaged over all eyes was slightly raised at the central fovea (from 0.658 to 0.670 D.U. (relative 
change +1.8 %), p = 0.08) and most markedly at 2.0° (from 0.157 to 0.172 D.U. (+9.5 %), p < 0.001). Multivariate analy‑
ses, adjusting for sex, body mass and carotenoid supplement intake, revealed that MPOD increments, at any distance 
from the fovea, were slightly less pronounced in older eyes. Serum concentrations of lutein at follow‑up, presumably 
reflecting recent intake of antioxidant supplements, raised MPOD levels significantly at 1.0° and 2.0° (both p < 0.01) 
but not in the central fovea. Early AMD at baseline and ring‑like MPOD distribution did not significantly impact on 
MPOD changes over time. A ring‑like spatial distribution of MPOD persisted in over 80 % of the affected eyes.
Conclusions: Overall, the magnitude and spatial arrangement of MPOD was remarkably stable over time in elderly 
eyes. Significant MPOD rises in perifoveal regions probably indicate effects of lutein containing supplements. The 
persistence of ring‑like MPOD distributions over time seems to suggest their determination by anatomical structures.
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Background
Recent research has shown that the occurrence and pro-
gression of age-related macular degeneration (AMD), the 
leading cause of legal blindness among the elderly popula-
tion in industrialized countries [1], is mainly influenced by 
demographic, environmental and genetic factors [2–4]. The 
level of macular pigment in the central retina is thought to 
also have an impact on AMD, however, the precise roles 
and mechanisms of this process are not yet clearly under-
stood [5, 6]. Commonly, lutein meso-zeaxanthin and zeax-
anthin, known to accumulate in the macula as macular 
pigment (MP) [7] and having antioxidant and light-screen-
ing properties for short wavelengths, are hypothesized to 
protect the eye against the development of various degen-
erative retinal diseases, including AMD [8].
There is presently some debate as to whether a loss 
of MP is the result of progressed AMD or whether it is 
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a cause [9]. It seems conceivable that degenerative pro-
cesses cause impairments in transport and storage of 
lutein and zeaxanthin resulting in decreased MP in the 
retina [5]. On the other hand, a reduced availability and 
potentially also storability of carotenoids in the retina 
may independently lead to the degeneration of functional 
retinal tissue. Zeimer et al. [10] demonstrated that, after 
oral supplementation with lutein and zeaxanthin, an 
increase in MPOD can be detected only in areas where 
MPOD had been measurable before in persons with 
macular telangiectasia. Supplementation did not produce 
an increase in areas where MPOD had been lacking at 
baseline. These results are compatible with the hypoth-
esis that MP is stored in retinal tissue structures that are 
characteristic of an individual and that determine also the 
spatial patterns of MPOD distribution [11]: supplementa-
tion can therefore increase MPOD levels only where such 
storage facilities were pre-existing. Interestingly, ring-
like distributions of MPOD appear not to be affected by 
supplementation of lutein/zeaxanthin [12]. According to 
Tariq et al. [13] such ring-like patterns are highly inher-
itable and constant in individuals. These results support 
the idea that genetically determined structural compo-
nents are responsible for the storability and availability 
of MP in the macula and that successful supplementation 
with lutein or zeaxanthin always depends on macular 
microanatomy. Our recent study using optical coherence 
tomography supports such a concept [11].
It is also not entirely clear in which tissue compart-
ments the MP is stored. It is known to primarily accu-
mulate in the inner plexiform layer and the long cone 
receptor axons (Henle’s fibres) [14], and more recent 
studies have attributed Müller cells with the trafficking 
and storage of MP within the retina [15]. Thus, it has 
been hypothesized that low levels or loss of MP may be 
causal to the dysfunction or destruction of Müller cells. 
The latter may be associated with the ring-like MPOD 
distribution that is found in a certain proportion of reti-
nae [11].
To further elucidate these relationships, we investi-
gated whether the contents and the distribution pat-
terns of MP change over time with the ageing of elderly 
individuals [16]. The measurement of its optical density 
(MPOD) served as a non-invasive method of quantita-
tive MP assessment and it was prospectively analysed in 




Data were obtained from participants of the Münster 
Ageing and Retina Study (MARS), a longitudinal study 
designed to identify medical, environmental and genetic 
factors with implications for the pathogenesis and pro-
gression of early AMD [17, 18]. Eligibility criteria and 
examination protocols have been described in detail 
before [4, 17, 19]. In brief, patients were self-selected 
ophthalmology patients residing in the Münster region 
in North-Western Germany. Patients had to be aged 
between 60 and 80  years by the time the study started, 
had to have early AMD in at least one eye and no con-
traindications to pupil dilatation, no advanced cataracts 
or other factors impeding clear visualization of the cen-
tral retina. Additionally, a convenience sample consisting 
of spouses or friends of study participants and of other 
volunteers that were free of AMD, were included as a 
comparison group. All participants were of Caucasian 
origin.
The cohort baseline examinations (MARS I) of 1060 
participants took place from June 2001 to October 2003. 
The first cohort follow-up (MARS II) was carried out 
between November 2003 and August 2006 with 828 par-
ticipants attending (85.5 % of those eligible), of whom 722 
had gradable fundus photographs in both eyes. Between 
2007 and 2009, after a median time of 3.96  years, we 
re-examined 492 participants (MARS III, participation 
75.1 % of those eligible).
At each study visit, participants were interviewed by 
trained staff members using mostly identical, standard-
ized questionnaires. Detailed information was obtained 
on demographic characteristics, smoking, lifestyle, 
medical history, and the current use of medications and 
vitamin supplements, in particular those containing the 
carotenoids L and/or Z. Ophthalmological examinations 
were performed to determine the best corrected visual 
acuity (Early Treatment Diabetic Retinopathy Study 
charts) and by using slit-lamp microscopy. The spherical 
equivalent refractive error in each eye and the number of 
pseudophakic eyes were documented.
Stereoscopic digital fundus photography was per-
formed at an angle of 30° in both eyes, centred on the 
fovea. The grading of AMD stages was performed 
according to the Rotterdam Classification System [20] as 
described in detail before [2, 18]. The range of AMD signs 
was stratified into five severity stages: stage 0, no sign of 
AMD or hard drusen (<63 μm) only; stage 1, soft, distinct 
drusen (≥63  μm) only, or pigment epithelium changes 
only, no soft drusen (≥63  μm); stage 2, soft, indistinct 
drusen (≥125 μm) only, or soft distinct drusen (≥63 μm) 
with pigment epithelium changes; stage 3, soft, indistinct 
drusen (≥125 μm) with pigment epithelium changes; and 
stage 4, atrophic or neovascular AMD. Eyes were classi-
fied as having no AMD (stage 0 or 1), early AMD (stages 
2–3) or late stage AMD (stage 4). All baseline and follow-
up ophthalmologic examinations were conducted by spe-
cifically trained medical staff whose performance was 
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regularly certified. The follow-up visits involved the same 
examinations as the baseline (MARS I) visits [16, 19] plus 
additional components such as, e.g., MPOD measure-
ments which were included in MARS II and MARS III.
AMD was diagnosed in eyes with dilated pupils based 
on presence and severity of retinal lesions.
MPOD measurements
The two-wavelength autofluorescence (AF) method 
for measuring MPOD has been previously described 
[7, 21–24]. Briefly, it is based on the AF of lipofuscin, 
which is present in the retinal pigment epithelium (RPE) 
cells. Lipofuscin can be excited in  vivo between 400 
and 580 nm to emit its fluorescence in the 500–800 nm 
spectral range, whereas MP absorbs blue-light for wave-
lengths shorter than 550 nm, with a peak absorbance of 
460 nm. In the fovea, excitation light within the absorp-
tion range of MP is partially absorbed by the carotenoids, 
resulting in an area of reduced fluorescence. In order to 
measure the MPOD, the dual-wavelength approach of 
the AF method compares results from two excitation 
wavelengths that are differentially absorbed by the MP. 
Therefore, the dual-wavelength technique takes account 
of the non-uniform distribution of lipofuscin in the RPE 
but assumes that the shape of the excitation spectrum is 
constant over the macular area [19].
In our analyses, quantitative imaging was performed 
using a retinal angiograph (Heidelberg Retina Angio-
graph HRA 1; Heidelberg Engineering, Heidelberg, 
Germany), modified for the measurement of macular 
pigment. Excitation wavelengths used were 488 nm (well 
absorbed by MP) and 514  nm (minimally absorbed by 
MP). This method has been used in clinical studies and 
was described in detail before [12]. MPOD measure-
ments were added to the examination procedures dur-
ing MARS II and were subsequently also obtained in the 
participants of MARS III. All MPOD measurements were 
performed by at least two trained investigators using the 
same testing device and protocol throughout. Subjects 
with AF images of inadequate quality (n  =  83) (most 
commonly due to insufficient fixation by the study sub-
jects) were excluded as described before [19].
MP optical density profile and ring‑like structure
In consistency with our previous research on spatial dis-
tribution of MP we distinguished between eyes with and 
without ring-like MPOD structures and a third group of 
eyes with an intermediate structure [11, 16, 19]. Meas-
urement of spatial distribution has been described pre-
viously in detail. In brief, we analyzed the MP optical 
density maps and the radial density profiles. The latter 
were generated and graphically displayed by plotting the 
mean MPOD values that were calculated for each radius 
around the fovea in distances of up to 8°, displaying a pro-
file of grey scale values comparable to a cross-sectional 
cut through the foveola. In eyes where the fovea could not 
be defined automatically as the center of the Gaussian dis-
tribution fitted to the MPOD map, the center of the fovea 
was defined manually (Additional file 1: Figure S1).
Ring-like structures were defined as density profiles 
showing bimodal patterns consisting of a central peak 
of MPOD followed by a decline and a secondary peak of 
increased density on the slope of the profile. In those cases 
where the distribution of MPOD showed neither a strictly 
monotonic decline from the foveola to the periphery nor 
an explicit ring-like pattern, such eyes were labelled as 
having “intermediate distributions” and were treated as a 
third group of eyes besides those distinctively categorized 
as with or without ring-like structures [16].
For this study, we present the mean MP optical den-
sity averaged along an annulus with retinal eccentricity 
of 0.25°, 0.5°, 1.0° and 2.0° degrees and width of one pixel 
each. MPOD results are reported in dimensionless den-
sity units (D.U.).
Study participants
MPOD measurements were included as an expansion of 
the study protocol during the second half of MARS II: 
this defined the start of the MPOD sub-study reported 
herein. To better visualize the selection process see the 
flowchart in Fig. 1. There were 237 participants—provid-
ing 474 single eyes for the study—who had MPOD meas-
ured in both MARS II and in MARS III, and gradable 
fundus photographs in at least one eye. In addition, par-
ticipants were included in the study base only if they had 
a complete data set for potential confounders, that is, for 
age, sex, smoking, and body mass index (BMI) as meas-
ured at MARS II, and for serum concentrations of lutein 
and zeaxanthin as measured at MARS III. MPOD meas-
urements of sufficient quality and data on the presence or 
absence of a ring-like structure were available in 380 of 
the initial 474 study eyes which formed the data base for 
the progression analyses presented in this report.
We used self-reports on the use of lutein and zeax-
anthin (L/Z) containing vitamin supplements. These 
reports are highly variable due to the availability of an 
enormous amount of different preparations sold over the 
counter. Additionally, serum concentrations of lutein and 
zeaxanthin measured at the follow-up visit of MARS III 
helped to account for unmeasured lutein and zeaxanthin 
supplies at follow-up.
Statistical analysis
Unadjusted comparisons were made using two-sided paired 
t-tests for the comparison of mean MPOD values at baseline 
and at follow-up. Changes of MPOD over time (ΔMPOD) 
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were calculated by subtracting values measured in MARS III 
from those measured at baseline in MARS II. Multivariate 
regression methods were applied to model ΔMPOD at 0.25°, 
0.5°, 1.0° and 2.0° eccentricities in order to assess the impact 
of age at baseline, serum lutein/zeaxanthin levels, presence 
of AMD and presence of ring-like structure accounting for 
sex, BMI and self-reported intake of L/Z-containing sup-
plements. In sensitivity analyses, pseudophakia and spheri-
cal equivalent were additionally included in the models. 
As smoking prevalence was extremely low among the aged 
participants of this study, we did not include smoking in the 
models. To account for the interrelation between the paired 
eyes in the study sample, we applied linear mixed regression 
modelling. In addition, we assessed if the presence of ring-
like or intermediate structures changed between the two 
measurements. All analyses were performed using the Sta-
tistical Analysis System (SAS, version 9.4 for Windows, SAS 
Institute Inc., Cary, NC).
Results
The 380 study eyes originated from 237 individuals who 
were on average 70.5 years old at the start of the prospec-
tive follow-up. About two-thirds of the study eyes were 
from female participants and roughly one-third showed 
signs of early AMD while ring-like MPOD structures 
were found in about every fourth study eye (Table 1). The 
mean body mass index of the study participants was 27.0 
(standard deviation 4.2). Of note, current smoking was 
very uncommon in this aged study group (only 3 active 
smokers) and therefore not further considered in the fol-
lowing analyses.
Table  2 shows that after a median follow-up time of 
3.96  years, the mean MPOD values at 0.25°, summariz-
ing all eyes, was only slightly raised (+0.012 D.U., a 1.8 % 
relative increase over the baseline value; p =  0.08). The 
MPOD increment was also consistently low further away 
from the fovea, ranging from +0.011 to +0.015 D.U. (all 
p  <  0.05). In relative terms, however, the most promi-
nent and highly significant rise was observed at 2.0° with 
+9.6 % (p < 0.001). More detailed analyses, considering 
quintiles of MPOD change by location, confirmed this 
finding (Additional file 1: Figure S1).
Multivariate analyses (Table  3), adjusted for sex, body 
mass index, carotenoid supplementation, pseudophakia 
and spherical equivalent, revealed that older age at baseline 
was associated with statistically significant, reduced MPOD 
Fig. 1 Flowchart to visualize the recruitment of suitable study subjects
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changes at 1.0° (−0.020 D.U. per 5 year older age, p > 0.001) 
and 2.0° (−0.0075 D.U. and p  <  0.01, respectively); this 
effect was not present in the central regions of the retina. 
Lutein serum concentrations were directly related to 
MPOD increases; of note, these increments over time were 
detected exclusively at 1.0° (p < 0.01) and 2.0° (p < 0.001). 
The serum levels of zeaxanthin showed no association with 
MPOD. Furthermore, early AMD at baseline appeared 
unrelated to MPOD changes over time. Likewise, the pres-
ence of a ring-like MPOD distribution was not associated 
with significant changes of MPOD over time.
Distribution patterns of MPOD persisted in 301 of the 
380 eyes (79.2 %) during the study period (Fig. 2). Fifteen 
(17 %) of the 87 eyes with ring-like MPOD were re-clas-
sified as intermediate, and only 12 out of 224 (5.4 %) with 
no sign of a ring-like or intermediate MPOD distribution 
at baseline were now classified as ‘incident’ rings.
Discussion
In this prospective study of elderly eyes, the levels of 
macular pigment increased only mildly (between 1.8 and 
9.5 % relative change) over time and the spatial distribu-
tion was fairly stable. The MPOD increments were lower 
in eyes of older study participants, but this was statisti-
cally significant only at distances of 1.0° and 2.0° from the 
centre. Counterbalancing this was the effect of lutein in 
blood, presumably reflecting recent L/Z containing sup-
plement use, raising MPOD levels also mainly in the 
perifoveal regions. The presence of early AMD or ring-
like distributions at baseline had no obvious impact on 
MPOD alterations over time.
This is to our knowledge the first prospective obser-
vational study measuring MPOD changes in a cohort of 
elderly individuals who were not submitted to a study 
protocol involving systematic supplementation. The 
study cohort was reassessed after an average period of 
4  years. We aimed to elucidate the process that may, at 
least in parts, reflect the ‘natural course’ of individual 
MPOD levels and distributions in elderly eyes due to age-
ing, environmental factors and disease. This study was 
observational and non-interventional by nature, permit-
ting study individuals to start or stop the use of supple-
mentary prescriptions indistinctively. The self-reported 
utilization of lutein and/or zeaxanthin containing supple-
ments by study participants turned out to be highly varia-
ble probably due to recall errors. Supplements containing 
lutein and zeaxanthin in markedly varying concentra-
tions are sold in Germany over the counter in pharma-
cies, drug stores and supermarkets—and their numbers 
count in hundreds. Therefore, the elderly participants 
could neither precisely recall brand names nor strengths 
of the supplement or duration of its intake. To corrobo-
rate the self-reported supplement use we measured the 
concentrations of lutein and zeaxanthin in serum at the 
time of the follow-up examination assuming that these 
concentrations more objectively reflected the individual 
situation with regard to recent supply with lutein and 
zeaxanthin. We observed that, even after controlling for 
self-reported supplement use at baseline and at follow-
up, serum lutein concentrations were still significantly 
related to higher MPOD levels in the perifoveal region. 
By contrast, no MPOD changes were detected in the cen-
tral foveal areas. These findings are in line with evidence 
showing lutein is predominantly stored in the perifoveal 
area [25] while zeaxanthin is stored in the fovea where it 
is presumably more stable and less easily influenced by 
supplementation [5] as also confirmed by a lack of asso-
ciations with serum zeaxanthin in our study. This appears 
to also confirm previous reports postulating that the ana-
tomical structure of the fovea plays an important role in 
the way MP is distributed [26]. As suggested before [11], 
Table 1 Baseline characteristics of the study
MPOD macular pigment optical density
Number of study participants 237
Age at MARS II (years)
 Mean 70.5
 Standard deviation 4.8
Number of study eyes 380 (100 %)
Number of eyes from females 244 (64.2 %)
Eyes with
 Early AMD 150 (39.5 %)
 No AMD 230 (60.5 %)
MPOD distribution
 Ring‑like 87 (22.9 %)
 Intermediate 69 (18.2 %)
 Monotonically decreasing 224 (58.9 %)
Follow‑up time (years)
 Median 3.96
 Interquartile range 0.12
 Minimum 2.94
 Maximum 5.26
Table 2 Macular pigment optical density (MPOD, in  den-







Mean (SEM) Mean (SEM) Mean (SEM)
At 0.25° 0.658 (0.010) 0.670 (0.010) 0.012 (0.008) 0.0814
At 0.50° 0.568 (0.010) 0.583 (0.010) 0.014 (0.006) 0.0138
At 1.0° 0.449 (0.008) 0.461 (0.008) 0.011 (0.005) 0.0196
At 2.0° 0.157 (0.004) 0.172 (0.004) 0.015 (0.002) <0.0001
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the rather stable central load of MP is presumably attrib-
utable to the xanthophyll binding Müller cell cones, while 
in the periphery the cone axons store the MP. It appears 
that raised serum lutein is more easily integrated in the 
peripheral axon membranes than in the Müller cones, 
probably because zeaxanthin dominates capacities in the 
Table 3 Predictors of  the change of  MPOD (ΔMPOD) after  a median follow-up of  3.96  years; the results are presented 
as regression coefficients (β) from multivariate regression models
* Adjusted—in addition to variables in table—for sex, body mass index and carotenoid supplementation, pseudophakia and spherical equivalent
Change of MPOD (ΔMPOD)*
At 0.25° At 0.5° At 1.0° At 2.0°
Predictors β p value β p value β p value β p value
Age (per 5 years) −0.019 0.05 −0.015 0.10 −0.020 <0.001 −0.0075 0.01
Log serum lutein [microg/ml] at follow‑up −0.008 0.69 +0.013 0.41 +0.016 <0.01 +0.023 <0.001
Log serum zeaxanthin [microg/ml] at follow‑up −0.01 0.73 −0.009 0.70 −0.006 0.74 −0.004 0.67
AMD (vs. none) at baseline −0.006 0.75 −0.010 0.51 −0.007 0.55 +0.002 0.86
MPOD Ring (vs. none) at baseline +0.024 0.24 +0.009 0.57 +0.013 0.31 +0.013 0.06
Fig. 2 Cross‑classification of study eyes according to spatial distribution patterns of MPOD: comparison of baseline and follow‑up examinations. 
Ring_BL = ring‑like MPOD distribution at baseline. Intermediate_BL = intermediate MPOD distribution pattern at baseline. No Ring_BL = monoto‑
nously decreasing MPOD distribution at baseline. Ring_FU = ring‑like MPOD distribution at 3.96 years follow‑up. Intermediate_FU = intermediate 
MPOD distribution pattern at 3.96 years follow‑up. No Ring_FU = monotonously decreasing MPOD distribution at 3.96 years follow‑up
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latter. It would be interesting to determine whether this 
observation is entirely attributable to capacity of storage, 
micro-anatomical changes such as dislocations, crushing 
or squeezing of cell complexes, or whether degenerative 
processes influence the fluctuation of MPOD.
Of note, the average net change of MPOD over 
4 years was, despite being statistically significant at the 
more peripheral eccentricities, quantitatively small. In 
an attempt to disentangle the influential factors in this 
process, we found a tendency of old eyes to accumulate 
less MP in the retinal periphery. In the overall sum-
mary analyses of all eyes, this was counterbalanced by 
the MPOD rise in the same region attributable to higher 
lutein serum concentrations. It appears that the utiliza-
tion of MP containing supplements which was rising 
with age was leading to the positive net MPOD balance 
reported in Table 2.
Interestingly, and in line with previous findings [11, 
13], the presence and magnitude of ring-like distributions 
of MPOD remained fairly stable over time. This supports 
the view that the spatial MPOD patterns are individually 
rather stable features and that they derive rather from 
anatomical and/or genetic predetermination than from 
the influence of lifestyles, age or the availability of carote-
noids. Nevertheless, we observed variations in that some 
eyes with a ring were classified at follow-up as inter-
mediate (15/87) while some appeared as ‘incident’ ring 
structures. This variability may potentially be attribut-
able to the methods of classification of ring-like distribu-
tions from density profiles. These are dependent on the 
precise identification of the fovea center. However, the 
same technical equipment and the same trained observ-
ers carried out the analyses in this prospective study. The 
impact of surgical interventions (e.g., cataract removal) 
which may have improved the image quality between the 
first and the second examination was ruled out as a major 
biasing factor in sensitivity analyses.
Our finding that the presence of early AMD at base-
line was prospectively unassociated with MPOD change 
seems to indicate that the onset of AMD is not accompa-
nied by a concomitant marked loss of MP.
Previous studies suggested that the reasons for lower 
MPOD levels are female sex, smoking, ethnicity and 
older age [27]. In this prospective study sex was unrelated 
to MPOD change over time and the impact of age was 
only very modest; the impact of smoking could not be 
assessed due to the low number of current smokers, and 
all participants were Caucasian. Thus, it may appear that 
MPOD levels and distribution in well-nourished elderly, 
avoiding nutritional depletion, is a stable and well con-
served feature of the retina.
The strength of the presented report lies in its prospec-
tive design and the fact that measurements were repeated 
with consistent quality on a large number of eyes. As a 
major shortcoming we emphasize the difficulty of pre-
cisely and validly ascertaining the intake of supplements 
containing macular pigment components. Lutein levels 
in serum helped to account for this problem and we sup-
pose that these measurements probably captured most of 
the influence of recent supplement utilization.
Conclusion
In conclusion, MPOD was rather stable in levels and 
spatial arrangement over time in ageing eyes. Significant 
MPOD rises predominating in the perifoveal regions 
probably indicate effects of lutein containing supple-
ments. Eyes with early AMD showed no significant 
MPOD changes. The persistence of ring-like MPOD dis-
tributions over time seems to confirm previous reports 
suggesting that rings are mostly determined by anatomi-
cal structures.
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